Literature DB >> 23852127

Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.

Vivek Jain1, Wendy Hartogensis, Peter Bacchetti, Peter W Hunt, Hiroyu Hatano, Elizabeth Sinclair, Lorrie Epling, Tzong-Hae Lee, Michael P Busch, Joseph M McCune, Christopher D Pilcher, Frederick M Hecht, Steven G Deeks.   

Abstract

Background. CD4(+)/CD8(+) T-cell activation levels often remain elevated in chronic human immunodeficiency virus (HIV) infection despite initiation of antiretroviral therapy (ART). T-cell activation predicts early death and blunted CD4+ T-cell recovery during ART and may affect persistent HIV reservoir size. We investigated whether very early ART initiation is associated with lower on-therapy immune activation and HIV persistence. Methods. From a cohort of patients with early HIV infection (<6 months duration since infection) we identified persons who started ART early (<6 months after infection) or later (≥2 years after infection) and maintained ≥2 years of virologic suppression; at-risk HIV-negative persons were controls. We measured CD4(+)/CD8(+) T-cell activation (percent CD38(+)/HLA-DR(+)) and HIV reservoir size (based on HIV DNA and cell-associated RNA levels). Results. In unadjusted analyses, early ART predicted lower on-therapy CD8(+) T-cell activation (n = 34; mean, 22.1%) than achieved with later ART (n = 32; mean, 28.8%; P = .009), although levels in early ART remained elevated relative to HIV-negative controls (P = .02). Early ART also predicted lower CD4+ T-cell activation than with later ART (5.3% vs 7.5%; P = .06). Early ART predicted 4.8-fold lower DNA levels than achieved with later ART (P = .005), and lower cell-associated RNA levels (difference in signal-to-cutoff ratio (S/Co), 3.2; P = .035). Conclusions. ART initiation <6 months after infection is associated with lower levels of T-cell activation and smaller HIV DNA and RNA reservoir size during long-term therapy.

Entities:  

Keywords:  HIV antiretroviral therapy; HIV cure; HIV eradication; HIVreservoir; T-cell activation; early ART; inflammation

Mesh:

Substances:

Year:  2013        PMID: 23852127      PMCID: PMC3778965          DOI: 10.1093/infdis/jit311

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  43 in total

1.  Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.

Authors:  Miguel Goicoechea; Davey M Smith; Lin Liu; Susanne May; Allan R Tenorio; Caroline C Ignacio; Alan Landay; Richard Haubrich
Journal:  J Infect Dis       Date:  2006-05-18       Impact factor: 5.226

Review 2.  HIV infection, inflammation, immunosenescence, and aging.

Authors:  Steven G Deeks
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

3.  Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.

Authors:  Peter W Hunt; Huyen L Cao; Conrad Muzoora; Isaac Ssewanyana; John Bennett; Nneka Emenyonu; Annet Kembabazi; Torsten B Neilands; David R Bangsberg; Steven G Deeks; Jeffrey N Martin
Journal:  AIDS       Date:  2011-11-13       Impact factor: 4.177

4.  Differential effects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes.

Authors:  Sharat Srinivasula; Richard A Lempicki; Joseph W Adelsberger; Chiung-Yu Huang; Joshua Roark; Philip I Lee; Adam Rupert; Randy Stevens; Irini Sereti; H Clifford Lane; Michele Di Mascio; Joseph A Kovacs
Journal:  Blood       Date:  2011-05-11       Impact factor: 22.113

Review 5.  Towards an HIV cure: a global scientific strategy.

Authors:  Steven G Deeks; Brigitte Autran; Ben Berkhout; Monsef Benkirane; Scott Cairns; Nicolas Chomont; Tae-Wook Chun; Melissa Churchill; Michele Di Mascio; Christine Katlama; Alain Lafeuillade; Alan Landay; Michael Lederman; Sharon R Lewin; Frank Maldarelli; David Margolis; Martin Markowitz; Javier Martinez-Picado; James I Mullins; John Mellors; Santiago Moreno; Una O'Doherty; Sarah Palmer; Marie-Capucine Penicaud; Matija Peterlin; Guido Poli; Jean-Pierre Routy; Christine Rouzioux; Guido Silvestri; Mario Stevenson; Amalio Telenti; Carine Van Lint; Eric Verdin; Ann Woolfrey; John Zaia; Françoise Barré-Sinoussi
Journal:  Nat Rev Immunol       Date:  2012-07-20       Impact factor: 53.106

6.  Use of laboratory tests and clinical symptoms for identification of primary HIV infection.

Authors:  Frederick M Hecht; Michael P Busch; Bhupat Rawal; Marcy Webb; Eric Rosenberg; Melinda Swanson; Margaret Chesney; Jennifer Anderson; Jay Levy; James O Kahn
Journal:  AIDS       Date:  2002-05-24       Impact factor: 4.177

7.  Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden.

Authors:  Stephen R Cole; Sonia Napravnik; Michael J Mugavero; Bryan Lau; Joseph J Eron; Michael S Saag
Journal:  Am J Epidemiol       Date:  2009-12-09       Impact factor: 4.897

8.  High-level long-term white blood cell microchimerism after transfusion of leukoreduced blood components to patients resuscitated after severe traumatic injury.

Authors:  Tzong-Hae Lee; Teresa Paglieroni; Garth H Utter; Daniel Chafets; Robert C Gosselin; William Reed; John T Owings; Paul V Holland; Michael P Busch
Journal:  Transfusion       Date:  2005-08       Impact factor: 3.157

9.  Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia.

Authors:  Flavien Bernardin; Leslie Tobler; Irina Walsh; Joan Dunn Williams; Mike Busch; Eric Delwart
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

10.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.

Authors:  T W Chun; D Engel; M M Berrey; T Shea; L Corey; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

View more
  166 in total

Review 1.  Post-Treatment Controllers: Role in HIV "Cure" Research.

Authors:  Leslie R Cockerham; Hiroyu Hatano; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

2.  The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a US Public Health Setting.

Authors:  Christopher D Pilcher; Clarissa Ospina-Norvell; Aditi Dasgupta; Diane Jones; Wendy Hartogensis; Sandra Torres; Fabiola Calderon; Erin Demicco; Elvin Geng; Monica Gandhi; Diane V Havlir; Hiroyu Hatano
Journal:  J Acquir Immune Defic Syndr       Date:  2017-01-01       Impact factor: 3.731

3.  HIV-1 and HIV-2 differentially mature plasmacytoid dendritic cells into IFN-producing cells or APCs.

Authors:  Caroline M Royle; David R Graham; Simone Sharma; Dietmar Fuchs; Adriano Boasso
Journal:  J Immunol       Date:  2014-08-25       Impact factor: 5.422

4.  Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection.

Authors:  Lillian Seu; Steffanie Sabbaj; Alexandra Duverger; Frederic Wagner; Joshua C Anderson; Elizabeth Davies; Frank Wolschendorf; Christopher D Willey; Michael S Saag; Paul Goepfert; Olaf Kutsch
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

5.  Towards a cure for human immunodeficiency virus.

Authors:  Matthew C Pitman; Sharon R Lewin
Journal:  Intern Med J       Date:  2018-01       Impact factor: 2.048

6.  HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals.

Authors:  Fredrick H Omondi; Sandali Chandrarathna; Shariq Mujib; Chanson J Brumme; Steven W Jin; Hanwei Sudderuddin; Rachel L Miller; Asa Rahimi; Oliver Laeyendecker; Phil Bonner; Feng Yun Yue; Erika Benko; Colin M Kovacs; Mark A Brockman; Mario Ostrowski; Zabrina L Brumme
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

7.  Low proportions of CD28- CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection.

Authors:  Sulggi A Lee; Elizabeth Sinclair; Vivek Jain; Yong Huang; Lorrie Epling; Mark Van Natta; Curtis L Meinert; Jeffrey N Martin; Joseph M McCune; Steven G Deeks; Michael M Lederman; Frederick M Hecht; Peter W Hunt
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

8.  Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy.

Authors:  Charlene Wang; Mohamed Abdel-Mohsen; Matthew C Strain; Steven M Lada; Steven Yukl; Leslie R Cockerham; Christopher D Pilcher; Frederick M Hecht; Elizabeth Sinclair; Teri Liegler; Douglas D Richman; Steven G Deeks; Satish K Pillai
Journal:  J Infect Dis       Date:  2014-06-16       Impact factor: 5.226

9.  Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation.

Authors:  Thibaut Davy-Mendez; Sonia Napravnik; Oksana Zakharova; JoAnn Kuruc; Cynthia Gay; Charles B Hicks; Kara S Mcgee; Joseph J Eron
Journal:  J Acquir Immune Defic Syndr       Date:  2018-12-01       Impact factor: 3.731

10.  Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART.

Authors:  Alexander O Pasternak; Marlous L Grijsen; Ferdinand W Wit; Margreet Bakker; Suzanne Jurriaans; Jan M Prins; Ben Berkhout
Journal:  JCI Insight       Date:  2020-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.